★★★★★Verified
“Tirzepatide (Mounjaro) at Huashan endo. Three-visit titration plan, real labs, real doctor. Saving roughly $1,100/month vs the US — and they actually flagged a thyroid nodule on baseline ultrasound.”
减重代谢外科 · 2026
Bariatric & Metabolic Surgery,
Shanghai 6th 上海六院.
Laparoscopic sleeve gastrectomy, Roux-en-Y gastric bypass and SADI-S at China’s reference metabolic surgery centres. MDT pre-op optimisation, GLP-1 access, and structured 12-month follow-up.
★★★★★
5.0(2 verified reviews)
Shanghai 6th
Asia metabolic flagship
Pioneering Asian metabolic surgery research
Centre-published
$9.5–19k
All-in primary bariatric
vs $20–35k US private
International package
60–80%
T2D remission post-RYGB
At 1 year, T2D < 10 yr duration
Centre-published
MDT
Endo + nutrition + GI + psych
Pre-op optimization standard
Class A standard
Procedures & pathways
What this specialty
covers in China.
🔥 Trending
Sleeve gastrectomy
🔥 Trending
Roux-en-Y gastric bypass (RYGB)
SADI-S (single-anastomosis duodeno-ileal)
Revisional bariatric
GLP-1 + surgery combined
Read pathway →
Endoscopic sleeve gastroplasty (ESG)
Top centres
Reference and
Class A teaching hospitals.
Shanghai · NHC
Shanghai Sixth People’s Hospital 上海第六人民医院
National diabetes & obesity reference · Asian metabolic surgery flagship · high RYGB / SADI-S volume
Class A teaching
Shanghai
Shanghai Ninth People’s Hospital 上海第九人民医院
Class A · large bariatric programme · revisional surgery depth
Class A teaching
Shanghai
Zhongshan Hospital, Fudan 复旦中山
Class A · MDT bariatric programme · cardiometabolic comorbidity expertise
Class A teaching
Beijing
China-Japan Friendship Hospital 中日友好医院
Class A · obesity MDT · GLP-1 / surgery combined pathway
Class A teaching
Centre comparison
At a glance.
Indicative starting price for this specialty: $9,500–19,000 all-in international-patient package, depending on procedure complexity and centre.
| Hospital | City | Tier | NHC | JCI | Strength |
|---|---|---|---|---|---|
| Shanghai Sixth People’s Hospital 上海第六人民医院 | Shanghai | Class A teaching | ✓ | — | National diabetes & obesity reference · Asian metabolic surgery flagship · high RYGB / SADI-S volume |
| Shanghai Ninth People’s Hospital 上海第九人民医院 | Shanghai | Class A teaching | — | — | Class A · large bariatric programme · revisional surgery depth |
| Zhongshan Hospital, Fudan 复旦中山 | Shanghai | Class A teaching | — | — | Class A · MDT bariatric programme · cardiometabolic comorbidity expertise |
| China-Japan Friendship Hospital 中日友好医院 | Beijing | Class A teaching | — | — | Class A · obesity MDT · GLP-1 / surgery combined pathway |
NHC = National Health Commission designation as National Clinical Research Centre / National Medical Centre / National Clinical Key Specialty. JCI = Joint Commission International accreditation. Class A teaching = 三级甲等, China’s top hospital tier.
Patient reviews
What patients say about bariatric & metabolic surgery in China.
★★★★★Verified
“Wegovy in the US was $1,400 per month with insurance gymnastics. At Shanghai Sixth, the same drug from the hospital pharmacy is $280, and I got a proper endocrinology workup before they prescribed it.”
FAQ
Bariatric & Metabolic Surgery in China — answered.
- Why China for metabolic surgery?
- Three reasons: (1) Shanghai Sixth People’s Hospital is China’s designated national diabetes and obesity reference centre and the Asian flagship for metabolic surgery research; (2) MDT pre-operative optimisation (endocrinology + nutrition + GI + psych) is standard at top centres; (3) all-in package pricing of $9,500–19,000 vs $20,000–35,000 US private-payer, with comparable laparoscopic technique and outcomes.
- What outcomes can I expect?
- From centre-published data at top Chinese centres: average %TWL (total weight loss) at 1 year — sleeve 25–30%, RYGB 30–35%, SADI-S 35–40%. T2D remission at 1 year: 50–70% post-sleeve, 60–80% post-RYGB, 70–85% post-SADI-S in patients with T2D < 10 years duration and preserved beta-cell function. Outcomes track published Western series for matched case mix.
- GLP-1 vs surgery — when to consider which?
- Both are powerful T2D and obesity interventions and increasingly used in combination. GLP-1 (semaglutide / tirzepatide) is reversible, oral / injectable, and effective at 14–22% TWL. Surgery is more durable, with stronger T2D remission rates at higher BMI. Many patients now combine — GLP-1 pre-op for surgical-risk reduction, then surgery for durable effect, with GLP-1 added back if regain occurs. The MDT will frame the option set for your phenotype.
Want a written centre-match shortlist
in 48 hours?
Tell us the clinical question and your travel window. We return two written centre-match shortlists for bariatric & metabolic surgery — including subspecialty fit, English-workflow status, and starting prices.